Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Since the late 1980s, mutations in the RAS genes have been recognized as major oncogenes with a high occurrence rate in human cancers. Such mutations reduce the ability of the small GTPase RAS to hydrolyze GTP, keeping this molecular switch in a constitutively active GTP-bound form that drives, unchecked, oncogenic downstream signaling. One strategy to reduce the levels of active RAS is to target guanine nucleotide exchange factors, which allow RAS to cycle from the inactive GDP-bound state to the active GTP-bound form. Here, we describe the identification of potent and cell-active small-molecule inhibitors which efficiently disrupt the interaction between KRAS and its exchange factor SOS1, a mode of action confirmed by a series of biophysical techniques. The binding sites, mode of action, and selectivity were elucidated using crystal structures of KRAS G12C –SOS1, SOS1, and SOS2. By preventing formation of the KRAS–SOS1 complex, these inhibitors block reloading of KRAS with GTP, leading to antiproliferative activity. The final compound 23 (BAY-293) selectively inhibits the KRAS–SOS1 interaction with an IC 50 of 21 nM and is a valuable chemical probe for future investigations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BAY-293, a potent SOS1 inhibitor, was recently found to synergize with ARS-853 to inhibit Ras activation and cell proliferation by disrupting Ras-SOS1 interaction (Table 3).79”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Selective SOS1 inhibitors, such as BAY-293 and BI-3406, have demonstrated synergistic antiproliferative activity in the KRASG12C mutant cell line by inhibiting the RAS-RAF-MEK-ERK pathway [66,67].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Son of sevenless 1 (SOS1) and SH2-containing protein tyrosine phosphatase (SHP2) are the two most critical targets in the RAS signaling pathway [61, 62].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, mutant KRAS can also activate wild-type RAS through SOS1 and subsequently RTK downstream signaling, leading to resistance to KRAS-targeted therapies [96].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As evidenced by reports of small molecules targeting the RAS GEF SOS1, inhibition of GEF activity would thus arrest the given GTPase signaling pathways, constituting a promising target for small-molecule therapeutic development (11, 12).”
From RHO to the DOCK for GDP disembarking: Structural insights into the DOCK GTPase nucleotide exchange factors (2021) · cites this paper as [11]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915 · cited 2×
“Models were rebuilt using Coot (40) and refined using REFMAC (41).”
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353 · cited 1×
“Datasets were collected at the Helmholtz-Zentrum Berlin in Germany, at the European Synchrotron Radiation Facility in Grenoble, France, or at the PETRA III synchrotron in Hamburg, Germany; processed using XDS (36) and XDSAPP (37); and solved using Molecular Replacement with Phaser (38) from the CCP4 suite (39).”
MethodREFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,317
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“(Right) The combination index was calculated according to the median-effect model of Chou– Talalay (43); a value below 0.”
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
Schüttelkopf, A. W., & van Aalten, D. M. F. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904011679 · Cited by 4,804 · cited 3×
“Ligand models were generated using BIOVIA Discovery Hillig et al. PNAS | February 12, 2019 | vol. 116 | no. 7 | 2559 BI O CH EM IS TR Y Studio (Dassault Systèmes) and parameter files calculated with PRODRG (42).”
MethodInfluentialTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“For oncogenic RAS mutants, however, the GAP activity is impaired or greatly reduced, resulting in permanent activation, which is the basis of oncogenic RAS signaling (7); for example, through the RAS-RAF-MEK-ERK and RAS-PI3K-PDK1-AKT pathways, both essential to cell survival and proliferation (8).”
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Identification and characterization of essential genes in the human genome
Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., & Sabatini, D. M. (2015) · Science · doi:10.1126/science.aac7041 · Cited by 1,617 · cited 2×
“Next, the downstream effects of the SOS1 inhibitors were analyzed by assays quantifying phospho-ERK (pERK) levels in K-562 cells, a tumor cell line for which sensitivity to SOS1 inhibition by CRISPR knockout has been reported (35).”
Stamos, J., Sliwkowski, M. X., & Eigenbrot, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207135200 · Cited by 1,574 · cited 1×
“Substituents in position 2 result in a steric clash with the hinge region of protein kinases and thereby abrogate the crucial interaction of the aminoquinazoline core with the hinge region, as illustrated for the case of the EGFR kinase inhibitor erlotinib (33) (SI Appendix, Fig.”
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · cited 1×
“This is based on findings that (i) these covalent inhibitors selectively bind to the GDP-bound, but not to the GTP-bound, KRAS protein and (ii) compared with other mutant KRAS proteins, KRAS undergoes nucleotide cycling within cells and, therefore, requires reactivation by exchange factors (11, 13).”
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene
Parada, L. F., Tabin, C. J., Shih, C., & Weinberg, R. A. (1982) · Nature · doi:10.1038/297474a0 · Cited by 944
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Vigil, D., Cherfils, J., Rossman, K. L., & Der, C. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2960 · Cited by 819 · cited 2×
“The most-studied GEF for RAS is the protein Son of Sevenless (SOS) for which two human isoforms, SOS1 and SOS2, are known (16).”
Der, C. J., Krontiris, T. G., & Cooper, G. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.11.3637 · Cited by 800
The structural basis of the activation of Ras by Sos
Boriack-Sjodin, P. A., Margarit, S. M., Bar-Sagi, D., & Kuriyan, J. (1998) · Nature · doi:10.1038/28548 · Cited by 799 · cited 3×
“Superimposition of the cdc25 domains of the fragment-bound KRAS–SOS1 crystal structures reported here with the HRAS–SOS1 complex that has an additional HRAS molecule bound to the allosteric site (PDB ID code 1NVU) revealed that RAS engagement at the allosteric site does not affect the fragment binding site.”
InfluentialStephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 1×
“the oncogenic G12C mutant of KRAS because of its clinical importance in lung cancer (24).”
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · cited 9×
“This is based on findings that (i) these covalent inhibitors selectively bind to the GDP-bound, but not to the GTP-bound, KRAS protein and (ii) compared with other mutant KRAS proteins, KRAS undergoes nucleotide cycling within cells and, therefore, requires reactivation by exchange factors (11, 13).”
InfluentialAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · cited 8×
“We have shown that the combination of our SOS1 inhibitor with ARS-853, a covalent inhibitor of KRASG12C, results in synergistic antiproliferative activity in a KRASG12C-mutated cell line (Fig.”
InfluentialDirect small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641 · cited 1×
“Recent strategies to directly inhibit RAS have focused on (i) targeting Cys12 of the oncogenic mutant KRAS with covalent inhibitors, (ii) RAS–effector interactions to disrupt downstream signaling, or (iii) inhibiting the RAS–GEF interactions to prevent reloading with GTP (10).”
Santos, E., Tronick, S. R., Aaronson, S. A., Pulciani, S., & Barbacid, M. (1982) · Nature · doi:10.1038/298343a0 · Cited by 623
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614 · cited 1×
“Additionally, attempts to inhibit RAS indirectly by targeting farnesyl transferases have not yet yielded approved drugs (9).”
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490 · cited 2×
“Biochemical characterization revealed that 1 inhibited SOS1-mediated loading of KRAS with GTP much more efficiently than the direct KRAS inhibitor, reference R2 (29) (Fig.”
BackgroundMethodMargarit, S. M., Sondermann, H., Hall, B. E., Nagar, B., Hoelz, A., Pirruccello, M., Bar-Sagi, D., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00149-1 · Cited by 480 · cited 1×
“SOS1 features two distinct RAS binding sites: a catalytic site and an additional allosteric RAS binding site (28).”
KRAS Alleles: The Devil Is in the Detail
Haigis, K. M. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.08.006 · Cited by 373 · cited 1×
“For oncogenic RAS mutants, however, the GAP activity is impaired or greatly reduced, resulting in permanent activation, which is the basis of oncogenic RAS signaling (7); for example, through the RAS-RAF-MEK-ERK and RAS-PI3K-PDK1-AKT pathways, both essential to cell survival and proliferation (8).”
BackgroundStructural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor
Renault, L., Guibert, B., & Cherfils, J. (2003) · Nature · doi:10.1038/nature02197 · Cited by 320 · cited 1×
“Results In our efforts to identify inhibitors of mutant RAS for cancer treatment, we initiated two parallel approaches: (i) a fragment screen was performed to identify inhibitors via KRAS–SOS1 complex stabilization, in analogy to the inhibition of the small GTPase ARF by brefeldin A (25); and (ii) a high-throughput sc…”
An orthosteric inhibitor of the Ras-Sos interaction
Patgiri, A., Yadav, K. K., Arora, P. S., & Bar-Sagi, D. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.612 · Cited by 295
Sparta, K. M., Krug, M., Heinemann, U., Mueller, U., & Weiss, M. S. (2016) · Journal of Applied Crystallography · doi:10.1107/s1600576716004416 · Cited by 285
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Burns, M. C., Sun, Q., Daniels, R. N., Camper, D., Kennedy, J. P., Phan, J., Olejniczak, E. T., Lee, T., Waterson, A. G., Rossanese, O. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315798111 · Cited by 199 · cited 3×
“The same pocket was recently reported for fragment hits targeting HRAS– SOS1 (19) and for SOS1 activators (21, 22).”
Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices
Leshchiner, E. S., Parkhitko, A., Bird, G. H., Luccarelli, J., Bellairs, J. A., Escudero, S., Opoku-Nsiah, K., Godes, M., Perrimon, N., & Walensky, L. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413185112 · Cited by 157 · cited 1×
“Attempts to inhibit the RAS–SOS interaction via peptides mimicking an orthosteric SOS helix identified hydrocarbon-stapled peptides with nanomolar affinity, but only low cellular activity (17, 18).”
BackgroundA Ras-induced conformational switch in the Ras activator Son of sevenless
Freedman, T. S., Sondermann, H., Friedland, G. D., Kortemme, T., Bar-Sagi, D., Marqusee, S., & Kuriyan, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608127103 · Cited by 157
Winter, J. J. G., Anderson, M., Blades, K., Brassington, C., Breeze, A. L., Chresta, C., Embrey, K., Fairley, G., Faulder, P., Finlay, M. R. V., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501660t · Cited by 119 · cited 3×
“The same pocket was recently reported for fragment hits targeting HRAS– SOS1 (19) and for SOS1 activators (21, 22).”
Mammalian Son of Sevenless Guanine Nucleotide Exchange Factors: Old Concepts and New Perspectives
Rojas, J. M., Oliva, J. L., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911408078 · Cited by 84
Mott, H. R., Carpenter, J. W., & Campbell, S. L. (1997) · Biochemistry · doi:10.1021/bi962790o · Cited by 74 · cited 1×
“Crystals of the KRAS–SOS1 complex were obtained using KRAS, a KRAS construct containing the mutation C118S to increase stability (26), as well as a triple mutation (D126E-T127S-K128R) identified in a surface mutation screen (SI Appendix, Supplementary Materials and Methods).”
MethodNovel Substituted Quinazolines for Potent EGFR Tyrosine Kinase Inhibitors
Cruz‐López, O., Conejo‐García, A., Nunez, M. C., Kimatrai, M., García-Rubiño, M. E., Morales, F., Gómez‐Pérez, V., & Campos, J. M. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794940824 · Cited by 62 · cited 1×
“Compound 1 shows structural similarity with known kinase inhibitors, such as the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib (32), and indeed inhibits EGFR kinase with an IC50 of 580 nM (SI Appendix, Table S3).”
Rational Design of Small Molecule Inhibitors Targeting the Ras GEF, SOS1
Evelyn, C. R., Duan, X., Biesiada, J., Seibel, W. L., Meller, J., & Zheng, Y. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.018 · Cited by 60
Burns, M. C., Howes, J. E., Sun, Q., Little, A. J., Camper, D. V., Abbott, J. R., Phan, J., Lee, T., Waterson, A. G., Rossanese, O. W., et al. (2018) · Analytical Biochemistry · doi:10.1016/j.ab.2018.01.025 · Cited by 47 · cited 2×
“The same pocket was recently reported for fragment hits targeting HRAS– SOS1 (19) and for SOS1 activators (21, 22).”
Howes, J. E., Akan, D. T., Burns, M. C., Rossanese, O. W., Waterson, A. G., & Fesik, S. W. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0666 · Cited by 42 · cited 2×
“Surprisingly, rather than inhibition, some of these binders activated the SOS1mediated nucleotide exchange, resulting in biphasic modulation of RAS signaling through negative feedback on SOS1 (23).”
Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective
Sautier, B., Nising, C. F., & Wortmann, L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608270 · Cited by 14
Self-citationSlater, M. J., & Vinter, A. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527665143.ch13 · Cited by 4
Cited by
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.013 · Cited by 820
“, 2010), and inhibition of SOS1 and KRAS is an emerging therapeutic strategy for KRAS mutant cancers (Hillig et al., 2019; O’Bryan, 2019).”
BackgroundTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 659
Metadata
- Authors
- Hillig, R. C., Sautier, B., Schroeder, J., Moosmayer, D., Hilpmann, A., Stegmann, C. M., Werbeck, N. D., Briem, H., Boemer, U., Weiske, J., Badock, V., Mastouri, J., Petersen, K., Siemeister, G., Kahmann, J. D., Wegener, D., Böhnke, N., Eis, K., Graham, K., Wortmann, L., von Nussbaum, F., & Bader, B.
- Affiliations
- Bayer (Germany) (DE)
- Evotec (Germany) (DE)
- Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany;
- Corresponding author
- Hillig, Roman C.
- Bader, Benjamin
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2019-01-25
- Volume
- 116
- Issue
- 7
- Pages
- 2551-2560
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6377443
- OpenAlex
- W2912277053
- Cited by
- 388
- References
- 43
- Citations by year
- 2026: 29 · 2025: 45 · 2024: 67 · 2023: 65 · 2022: 62 · 2021: 61 · 2020: 43 · 2019: 16
- FWCI
- 15.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Desy publication database (The Deutsches Elektronen-Synchrotron) (submittedVersion, cc-by-nc-nd)
- HZB Repository (Helmholtz-Zentrum Berlin für Materialien und Energie GmbH (HZB)) (submittedVersion, other-oa)
- Repository of Futwangen University of Applied Sciences (Furtwangen University) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- SOS1 inhibitor, KRAS, Ras activation, guanine nucleotide exchange factor, small molecule inhibitors, KRAS G12C, SOS2, GTP loading, oncogenic Ras mutations, antiproliferative activity, chemical probes
- MeSH terms
- Cell Line, Humans, Protein Binding, Signal Transduction, Proto-Oncogene Proteins p21(ras), Crystallography, X-Ray, SOS1 Protein, Fluorescence Resonance Energy Transfer, Drug Discovery, High-Throughput Screening Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.